Search

1 to 10 of 194
Sort by

Library Entry
IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors

The IL-17 family cytokines are potent drivers of colorectal cancer (CRC) development. The authors and others have shown that IL-17 mainly signals to tumor cells to promote CRC, but the underlying mechanism remains unclear. IL-17 also dampens Th1-armed anti-tumor immunity, in part by attracting...


Event
Immuno-Oncology Young Investigators' Forum

Presented by The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. (CEC) in collaboration with the Society for Immunotherapy of Cancer. This program is ideally suited for North American-based junior faculty, fellows, and postdoctoral researchers (MDs, DOs,...

 04-16-2020 08:00 - 04-18-2020 20:00 CT
 Houston TX


Library Entry
Immunotherapy for the Treatment of Head & Neck Cancers - A Patient Resource Guide

Learning you have head and neck cancer can fell overwhelming. Give yourself time to digest the news, and then focus on learning as much as you can about your exact diagnosis. Knowing ket information will better prepare you to make well-informed decisions with your doctor. This guide, published...

2019 Immunotherapy H&N.pdf


Library Entry
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. The authors applied mass spectrometry (MS) immunopeptidomics to investigate neoantigen presentation and whether this can be augmented...


Library Entry
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have demonstrated that...




Library Entry
Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer

Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane- and platinum-based chemotherapy. Thus, there is an urgent need to develop novel...